Biodefense Market Size, Share & Analysis Report, 2023-2032
The global biodefense market size was exhibited at USD 15.9 billion in 2022 and is projected to hit around USD 26.40 billion by 2032, growing at a CAGR of 5.2% during the forecast period 2023 to 2032.
Key Pointers:
Biodefense Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 16.73 Billion |
|
Market Size by 2032 |
USD 26.40 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 5.2% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Product |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
XOMA corporation; Altimmune Inc. Emergent Biosolutions Inc.; Dynavax Technologies Corporation; SIGA Technologies; Elusys Therapeutics Inc.; Ichor Medical Systems; Dynport Vaccine Company; Cleveland Biolabs; Bavarian Nordic; Ology Bioservices; Alnylam Pharmaceuticals Inc. |
Biodefense is a set of medical or military measures. These are taken in response to the demand for restoring the biosecurity of a country against biological toxins or infectious agents. The agents can be used with the intent to kill or infect humans, animals, or the environment and to instigate biological warfare. Biological agents used during bioterrorism are usually living organisms. These can include bacteria, viruses, fungi, or toxins that are deliberately used to sicken and kill creating social and economic turmoil. Factors such as the presence of favorable government initiatives in the U.S., growing investment from private players, increased government focus and funding towards biodefense strategies, and the growing prevalence of various agents such as the Ebola virus, Zika virus, and flu are driving the overall market growth.
The advent of technological advancements in the field of genetic engineering and biotechnology in the last decades has offered ease in modification of these fatal, and naturally occurring viruses which can be re-engineered to cause devastation. Moreover, these organisms can be easily obtained which makes biodefense a crucial aspect for countries around the world. Biological agents that have been used as a carrier for bioterrorism in the past include anthrax, botulism, and chemical & nuclear agent. This led to serious economic loss.
These instances drove governments around the world to engage in biodefense acts, treaties, and policies to counter biological threats, reduce risks, and prepare for, respond to, and recover from bioterrorism incidents. Since the anthrax bio-terrorism act that was carried out in 2001 through the mail, the National Institute of Infectious disease has played a vital role in developing medical products and strategies to counter bioterrorism and emerging and re-emerging infectious diseases by carrying out continuous research to diagnose, treat, and prevent them, whether deliberate or naturally occurring.
Governments of many countries remain committed to collaboration with several international partners to support response activities and increase preparedness. For instance, an experimental single-dose Ebola vaccine manufactured by Merck [rVSV-ZEBOV-GP] has been authorized for safe use by the World Health Organization and DRC MoH. As of November 17, 2019, approximately 250,000 persons at risk for Ebola have been vaccinated.
Developed economies are sending aid to countries with weak medical infra and low research capabilities many companies like Bavarian Nordic and Ology Bioservices are researching Ebola and Zika virus. The introduction of the Project BioShield Act was a strategic decision to increase funding for procuring, developing, and utilizing medical countermeasures against biological, chemical, radiological, and nuclear (CBRN) warfare agents. These above-mentioned factors and the rising risk of prevalence of the infectious disease is expected to boost the market growth.
Some of the prominent players in the Biodefense Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Biodefense market.
By Product
By Region
Chapter 1 Methodology And Scope
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective - 1
1.10.2 Objective - 2
1.10.3 Objective - 3
1.10.4 Objective - 4
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Biodefence Market: Variables, Trends, & Scope
3.1 Market Segmentation And Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Presence Of Favorable Government Initiatives In The U.S.
3.2.2.1 Biodefense Funding In Fy 2016 - 2021 By Federal Agency
3.2.2.2 Emergency Use Authorization Of Medical Products
3.2.2.3 Project Bioshield Act
3.2.2.4 Growing Investment From Private Players
3.2.3 Growing Prevalence Of Various Agents Such As Ebola Virus, Zika Virus, Flu, And Others
3.2.4 Market Restraint Analysis
3.2.4.1 Low Market Penetration In Developing And Underdeveloped Countries
3.3 Penetration & Growth Prospect Mapping
3.4 Biodefence: Market Analysis Tools
3.4.1 Industry Analysis - Porter’s
3.4.2 Pestel Analysis
3.5 Biodefense Competitive Scenario, 2015
3.5.1 Biological Defense
3.5.1.1 Biological Defense: Product Pipeline
3.5.2 Chemical Defense
3.5.2.1 Chemical Defense: Product Pipeline
3.5.3 Nuclear/Radiological Defense
3.5.3.1 Nuclear/Radiological Defense: Product Pipeline Analysis
Chapter 4 Biodefence Market: Product Segment Analysis
4.1 Biodefence: Agent Market Share Analysis, 2023 & 2032
4.2 Anthrax
4.2.1 Biodefense Against Anthrax Market Estimates And Forecasts, 2020 - 2032
4.3 Smallpox
4.3.1 Biodefense Against Smallpox Market Estimates And Forecasts, 2020 - 2032
4.4 Botulism
4.4.1 Biodefense Against Botulism Market Estimates And Forecasts, 2020 - 2032
4.5 Radiation/Nuclear
4.5.1 Biodefense Against Radiation/Nuclear Market Estimates And Forecasts, 2020 - 2032
4.5.2 Others
4.5.2.1 Other Biodefense Products Market, 2020 - 2032
Chapter 5 Biodefence Market: Regional Analysis
5.1 Biodefence: Regional Market Share Analysis, 2023 & 2032
5.2 North America
5.2.1 North America Biodefence Market, 2020 - 2032
5.2.2 U.S.
5.2.2.1 U.S. Biodefence Market, 2020 - 2032
5.2.3 Canada
5.2.3.1 Canada Biodefence Market, 2020 - 2032
5.3 Europe
5.3.1 Europe Biodefence Market, 2020 - 2032
5.3.2 U.K.
5.3.2.1 U.K. Biodefence Market, 2020 - 2032
5.3.3 Germany
5.3.3.1 Germany Biodefence Market, 2020 - 2032
5.3.4 France
5.3.4.1 France Biodefence Market, 2020 - 2032
5.3.5 Italy
5.3.5.1 Italy Biodefence Market, 2020 - 2032
5.3.6 Spain
5.3.6.1 Spain Biodefence Market, 2020 - 2032
5.3.7 Denmark
5.3.7.1 Denmark Biodefence Market, 2020 - 2032
5.3.8 Sweden
5.3.8.1 Spain Biodefence Market, 2020 - 2032
5.3.9 Norway
5.3.9.1 Norway Biodefence Market, 2020 - 2032
5.4 Asia Pacific
5.4.1 Asia Pacific Biodefence Market, 2020 - 2032
5.4.2 China
5.4.2.1 China Biodefence Market, 2020 - 2032
5.4.3 India
5.4.3.1 India Biodefence Market, 2020 - 2032
5.4.4 Japan
5.4.4.1 Japan Biodefence Market, 2020 - 2032
5.4.5 Australia
5.4.5.1 Australia Biodefence Market, 2020 - 2032
5.4.6 Thailand
5.4.6.1 Thailand Biodefence Market, 2020 - 2032
5.4.7 South Korea
5.4.7.1 South Korea Biodefence Market, 2020 - 2032
5.5 Latin America
5.5.1 Latin America Biodefence Market, 2020 - 2032
5.5.2 Brazil
5.5.2.1 Brazil Biodefence Market, 2020 - 2032
5.5.3 Mexico
5.5.3.1 Mexico Biodefence Market, 2020 - 2032
5.5.4 Argentina
5.5.4.1 Argentina Biodefence Market, 2020 - 2032
5.6 MEA
5.6.1 MEA Biodefence Market, 2020 - 2032
5.6.2 South Africa
5.6.2.1 South Africa Biodefence Market, 2020 - 2032
5.6.3 Saudi Arabia
5.6.3.1 Saudi Arabia Biodefence Market, 2020 - 2032
5.6.4 UAE
5.6.4.1 UAE Biodefence Market, 2020 - 2032
5.6.5 Kuwait
5.6.5.1 Kuwait Biodefence Market, 2020 - 2032
Chapter 6 Company Profiles
6.1.1 Xoma Corporation
6.1.1.1 Company Overview
6.1.1.2 Financial Performance
6.1.1.3 Product Benchmarking
6.1.1.4 Strategic Initiatives
6.1.2 Altimmune, Inc.
6.1.2.1 Company Overview
6.1.2.2 Financial Performance
6.1.2.3 Product Benchmarking
6.1.2.4 Strategic Initiatives
6.1.3 Emergent Biosolutions Inc.
6.1.3.1 Company Overview
6.1.3.2 Financial Performance
6.1.3.3 Product Benchmarking
6.1.3.4 Strategic Initiatives
6.1.4 Dynavax Technologies Corporation
6.1.4.1 Company Overview
6.1.4.2 Financial Performance
6.1.4.3 Strategic Initiatives
6.1.5 Siga Technologies, Inc.
6.1.5.1 Company Overview
6.1.5.2 Financial Performance
6.1.5.3 Product Benchmarking
6.1.5.4 Strategic Initiatives
6.1.6 Elusys Therapeutics, Inc.
6.1.6.1 Company Overview
6.1.6.2 Financial Performance
6.1.6.3 Product Benchmarking
6.1.6.4 Strategic Initiatives
6.1.7 Ichor Medical Systems
6.1.7.1 Company Overview
6.1.7.2 Financial Performance
6.1.7.3 Product Benchmarking
6.1.7.4 Strategic Initiatives
6.1.8 Dynport Vaccine Company Llc
6.1.8.1 Company Overview
6.1.8.2 Financial Performance
6.1.8.3 Product Benchmarking
6.1.8.4 Strategic Initiatives
6.1.9 Cleveland Biolabs
6.1.9.1 Company Overview
6.1.9.2 Financial Performance
6.1.9.3 Product Benchmarking
6.1.9.4 Strategic Initiatives
6.1.10 Bavarian Nordic
6.1.10.1 Company Overview
6.1.10.2 Financial Performance
6.1.10.3 Product Benchmarking
6.1.10.4 Strategic Initiatives
6.1.11 Ology Bioservices
6.1.11.1 Company Overview
6.1.11.2 Financial Performance
6.1.11.3 Product Benchmarking
6.1.11.4 Strategic Initiatives
6.1.12 Alnylam Pharmaceuticals, Inc.
6.1.12.1 Company Overview
6.1.12.2 Financial Performance
6.1.12.3 Product Benchmarking
6.1.12.4 Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers